An interventional study of Negative Pressure Wound Therapy and Negative Pressure Wound Therapy with Instillation in Necrotizing Soft Tissue Infections, sponsored by HealthPartners Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by HealthPartners Institute · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Soft Tissue Infections with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Soft Tissue Infections · United States.
Among the 39 studies in Soft Tissue Infections with a site in United States, this one is the 27th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, and was the 38th registered.
92 studies on the registry are indexed under Soft Tissue Infections; 14 are open to participants now.
Browse Soft Tissue Infections studies →5 of the 39 studies in Soft Tissue Infections with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–65
University of California, Irvine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages up to 18
Seattle Children's Hospital · Sites in United States
Ages 1–16
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Soft Tissue Infections studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 7
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 30 is below the median of 123 across 58 interventional studies indexed under Soft Tissue Infections.
Median enrollment 160 across the 31 interventional studies, 280 across the 7 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 39 have an industry lead sponsor. The 10 most frequent:
HealthPartners Institute is the lead sponsor of 168 studies on the registry; 21 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
HealthPartners Institute has 1 study filed under Soft Tissue Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Soft Tissue Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07120386HealthPartners InstituteIrrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections | 2026-12 |
| NCT06002607University of California, IrvineShorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections | 2026-12-01 |
| NCT05471908University of UtahFollow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Soft Tissue Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Necrotizing Soft Tissue Infections (NSTIs) are rapidly progressing infections that have a high morbidity and mortality, with the greatest morbidity related to managing the large wounds required to treat these patients. Initial treatment requires wide surgical removal of infected tissue and optimal management is essential to reducing morbidity in these patients. Negative pressure wound therapy (NPWT) is a widely used technology that has revolutionized wound management. NPWT is utilized across the spectrum of acute wounds, including routine postoperative incision management, traumatic wounds, and wounds related to surgical debridement of NSTIs which are frequently some of the most complicated of wounds encountered. Most NSTI cases at Regions Hospital currently utilize negative pressure wound therapy with instillation (NPWTi) where the wound is irrigated to clean out debris. Currently, there is a paucity of data comparing traditional NPWT and NPWTi and the choice of which device to use is left to surgeon discretion. This study is a first step at identifying the effects of NPWTi compared to NPWT alone on the care of NSTI patients. If the theoretical benefits of NPWTi over NPWT translate to practice, those treated with NPWTi would be expected to have a reduced rate of hospital readmission after their index hospitalization in addition to shorter time to definitive closure/coverage. This is a pilot study to assess the feasibility of enrolling patients with NSTIs in a randomized controlled trial to assess outcomes between the two devices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this arm will receive traditional Negative Pressure Wound Therapy (NPWT)
Device: Negative Pressure Wound Therapy
Patients in this arm will receive Negative Pressure Wound Therapy with Instillation of a hypochlorous acid solution (NPWTi)
Device: Negative Pressure Wound Therapy with Instillation
NPWT creates a vacuum seal over your wound to promote healing
Also known as: NPWT
NPWTi creates a vacuum seal over your wound and infuses the wound with hypochlorous acid (medical grade dilute bleach) to clean it.
Also known as: NPWTi
Unplanned hospital readmission
Did the patient have an unplanned readmission to the hospital (Y/N) within 30 days of discharge
Time frame: Within 30 days of discharge
Rate of healing
Time from index debridement to final coverage in days
Time frame: First operation and last operation
Number of operative interventions
Number of times the patient required an operation related to their NSTI during their hospital stay
Time frame: Through hospital discharge, median of 9 days
Unplanned vac change
Number of unplanned times the vacuum dressing had to be changed during their hospital stay
Time frame: Through hospital discharge, median of 9 days
Total vac changes
Total number of times the vacuum dressing was changed (planned + unplanned) during their hospital stay
Time frame: Through hospital discharge, median of 9 days
Bleeding
Bleeding at wound vac site (Y/N). During hospital stay
Time frame: Through hospital discharge, median of 9 days
Infection
New infection at wound vac site (Y/N). During hospital stay
Time frame: Through hospital discharge, median of 9 days
Hospital length of stay
Number of days spent in Hospital
Time frame: At hospital discharge, median of 9 days
Intensive Care Unit length of stay
Number of days spent in the Intensive Care Unit
Time frame: At hospital discharge, median of 9 days
Floor length of stay
Number of days spent inpatient in the hospital
Time frame: At hospital discharge, median of 9 days
Skilled Nursing Facility days
Number of days spent in a skilled nursing facility
Time frame: Up to 6 months after admission to skilled nursing facility
Discharge disposition
"Where was the patient discharged: ""1=Discharged/Transferred to a short-term general hospital for inpatient care 2=Discharged/Transferred to an Intermediate Care Facility (ICF) 3=Discharged/Transferred to home under care of organized home health service 4=Left against medical advice or discontinued care 5=Deceased/Expired 6=Discharged to home or self-care (routine discharge) 7=Discharged/Transferred to Skilled Nursing Facility (SNF) 8=Discharged/Transferred to hospice care 9=Discharged/Transferred to court/law enforcement. 10=Discharged/Transferred to inpatient rehab or designated unit 11=Discharged/Transferred to Long Term Care Hospital (LTCH) 12=Discharged/Transferred to a psychiatric hospital or psychiatric distinct part unit of a hospital 13=Discharged/Transferred to another type of institution not defined elsewhere"""
Time frame: At hospital discharge, median of 9 days
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 14 interventional studies with no phase under Soft Tissue Infections, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 16 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Dec 2026 and completion Oct 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.